Skip to main content
Premium Trial:

Request an Annual Quote

Empirical Bioscience EB Pure Plasmid Mini-Prep Kit

Empirical Bioscience has launched its new EB Pure Plasmid Mini-Prep Kit, which combines the firm's High-Bind technology with alkaline-SDS lysis of bacterial cells. The kit's High-Bind technology reversibly binds DNA or RNA under optimized conditions, removing proteins and other contaminants. It requires one to five milliliters of bacterial culture and delivers results in less than 30 minutes. It also isolates high-quality plasma or cosmid DNA for extraction up to 10 kilobases and yields up to 20 micrograms per preparation, the firm said.

The kit features an integrated pH indicator within the lysis buffer, which changes color to bright yellow when the lysis buffer reaches the pH level needed for DNA binding. The kit also includes a neutralization buffer, Rnase A, activation buffer, washing buffer, elution buffer, spin columns, and collection tubes. The components create a flexible kit for downstream applications, including automated fluorescent DNA sequencing and restriction enzyme digestion, Empirical added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.